Akebia Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Akebia Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $184.84 million for the year ending 2025.

  • Akebia Therapeutics, Inc. showed an increase of +256.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2013: $2.59 million | Q2 2013: $40.74 million | Q3 2013: $24.60 million | Q1 2014: $126.32 million | Q2 2014: $95.39 million | Q3 2014: $49.67 million | Q1 2015: $27.89 million | Q2 2015: $76.25 million | Q3 2015: $66.71 million | Q1 2016: $43.44 million | Q2 2016: $46.18 million | Q3 2016: $65.83 million | Q1 2017: $87.25 million | Q2 2017: $125.39 million | Q3 2017: $89.60 million | Q1 2018: $158.17 million | Q2 2018: $163.53 million | Q3 2018: $162.43 million | Q1 2019: $62.74 million | Q2 2019: $87.21 million | Q3 2019: $122.89 million | Q1 2020: $115.37 million | Q2 2020: $245.41 million | Q3 2020: $169.29 million | Q1 2021: $252.77 million | Q2 2021: $246.99 million | Q3 2021: $207.20 million | Q1 2022: $174.56 million | Q2 2022: $143.89 million | Q3 2022: $144.76 million | Q1 2023: $56.95 million | Q2 2023: $53.57 million | Q3 2023: $46.53 million | Q1 2024: $41.96 million | Q2 2024: $39.50 million | Q3 2024: $34.02 million | Q1 2025: $113.37 million | Q2 2025: $137.31 million | Q3 2025: $166.44 million.
  • Over the full 15 years of available data (2011 to 2025), Akebia Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 3,588.8%.
  • Historical annual values: Fiscal year 2025: $184.84 million | Fiscal year 2024: $51.87 million | Fiscal year 2023: $42.93 million | Fiscal year 2022: $90.47 million | Fiscal year 2021: $149.80 million | Fiscal year 2020: $228.70 million | Fiscal year 2019: $147.45 million | Fiscal year 2018: $104.64 million | Fiscal year 2017: $70.16 million | Fiscal year 2016: $187.34 million | Fiscal year 2015: $49.78 million | Fiscal year 2014: $32.78 million | Fiscal year 2013: $21.22 million | Fiscal year 2012: $1.64 million | Fiscal year 2011: $5.01 million.
  • Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: